WuXi PharmaTech, a provider of pharmaceutical R&D outsourcing services based in China, has signed a definitive agreement to acquire U.S.-based AppTec Laboratory Services, Inc. in a transaction totaling approximately $151 million, which includes about $11.7 million of AppTec debt. The acquisition provides WuXi PharmaTech with biologics capabilities and expertise, and a significant U.S. operation, expanding its customer base and market size. The combined business operations of the two com...